Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Gilead Sciences
Amgen
Allogene Therapeutics
Genmab
Auron Therapeutics, Inc.
Autolus Limited
Ascentage Pharma Group Inc.
Novartis
Senti Biosciences
AstraZeneca
Incyte Corporation
NextCure, Inc.
AbbVie
Newave Pharmaceutical Inc
Byondis B.V.
Acerta Pharma BV
AbbVie
Genmab
Aurigene Discovery Technologies Limited
Novartis
Kyowa Kirin Co., Ltd.
Servier
Accutar Biotechnology Inc
Wugen, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Schrödinger, Inc.
Advesya SAS
BlueSphere Bio, Inc
Biotroy Therapeutics
Astellas Pharma Inc
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Syndax Pharmaceuticals
AstraZeneca
Aptose Biosciences Inc.
Exscientia AI Limited
Hangzhou Polymed Biopharmaceuticals, Inc.
Curis, Inc.
AbbVie
Hemogenyx Pharmaceuticals LLC
Juventas Cell Therapy Ltd.
Servier
Ono Pharmaceutical Co. Ltd
Astellas Pharma Inc
Celgene
PureTech
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Tarapeutics Science Inc.
Genmab